title: Everolimus-induced activation of latentMycobacterium tuberculosisinfection in a patient with metastatic renal cell carcinoma.
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea.
authors.forename: So-Yeon
authors.initials: SY
authors.lastname: Jeon
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea.|Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju, Korea.
authors.forename: Ho-Young
authors.initials: HY
authors.lastname: Yhim
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea.|Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju, Korea.
authors.forename: Na-Ri
authors.initials: NR
authors.lastname: Lee
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea.|Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju, Korea.
authors.forename: Eun-Kee
authors.initials: EK
authors.lastname: Song
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea.|Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju, Korea.
authors.forename: Jae-Yong
authors.initials: JY
authors.lastname: Kwak
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea.|Research Institute of Clinical Medicine, Chonbuk National University Hospital, Jeonju, Korea.
authors.forename: Chang-Yeol
authors.initials: CY
authors.lastname: Yim
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D057915:Drug Substitution; D004359:Drug Therapy, Combination; D000068338:Everolimus / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D055985:Latent Tuberculosis / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000472:pathogenicity*; D009894:Opportunistic Infections / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000995:Antitubercular Agents; D000068338:Everolimus
keywords: Everolimus; Latent tuberculosis infection reactivation; Metastatic renal cell carcinoma
references.citation: Eur J Cancer. 2011 Jun;47(9):1287-98
references.pmid: 21481584
references.citation: Ann Transplant. 2011 Oct-Dec;16(4):107-10
references.pmid: 22210429
references.citation: Clin Infect Dis. 2013 Nov;57(10):1473-82
references.pmid: 23899676
references.citation: Thorax. 2013 Oct;68(10 ):955-61
references.pmid: 23976779